TY - JOUR
T1 - Clinical practice guidelines with recommendations for peripartum depression
T2 - A European systematic review
AU - Motrico, Emma
AU - Moreno-Peral, Patricia
AU - Uriko, Kristiina
AU - Hancheva, Camellia
AU - Brekalo, Maja
AU - Ajaz, Erilda
AU - Apter, Gisele
AU - Bramante, Alessandra
AU - Conejo-Cerón, Sonia
AU - Christoforou, Andri
AU - Dikmen-Yildiz, Pelin
AU - Evagorou, Olympia
AU - Fonseca, Ana
AU - Lupattelli, Angela
AU - Radoš, Sandra Nakić
AU - al Maach, Nadia
AU - Rodriguez-Muñoz, María F.
AU - Žutić, Maja
AU - Lambregtse - van den Berg, Mijke P.
N1 - FUNDING INFORMATION
This publication is based upon work from COST Action CA18138 – Research Innovation and Sustainable
Pan-European Network in Peripartum Depression Disorder (Riseup-PPD), supported by COST (European Cooperation
in Science and Technology), www.cost.eu.
Publisher Copyright: © 2022 The Authors. Acta Psychiatrica Scandinavica published by John Wiley & Sons Ltd.
PY - 2022/10
Y1 - 2022/10
N2 - Objective: This study aims to systematically review all Clinical Practice Guidelines (CPGs) with recommendations for peripartum depression in European countries. Methods: A systematic review according to the PRISMA statement was conducted. CPGs focussing on peripartum depression or with at least one specific recommendation for peripartum depression from European countries were selected. Searching was conducted in electronic databases (MEDLINE and PsycINFO), and by contacting professional societies and international experts until November 24th, 2021. Characteristics of the included CPGs and their recommendations were extracted. A methodological quality assessment was conducted using the AGREE-II tool. Results: A total of 239 records were identified after duplicate removal. Of these, 54 were examined for full-text inspection. The final selection yielded 14 CPGs from 11 European countries in 10 languages. Of them, 11 provided recommendations on pharmacological treatments, 10 on psychological treatment (e.g., cognitive-behavioural therapy), 10 on screening, 8 on diagnosis, 6 on other treatments (e.g., physical exercise), 5 on prevention, and 5 other recommendations (e.g., provide information). Regarding the overall methodological quality, only five (35.7%) guidelines were rated as of adequate quality, reaching a score ≥ 70% in the overall assessment of the AGREE-II instrument. Of the six AGREE-II domains, applicability scored the lowest and clarity of presentation scored the highest. Conclusion: The absence of CPGs in most European countries, the discrepancy in recommendations and the low methodological quality of the guidelines may lead to disparities and inequalities in peripartum depression management in Europe. The COST Action Riseup-PPD highlights key considerations for future guideline developers.
AB - Objective: This study aims to systematically review all Clinical Practice Guidelines (CPGs) with recommendations for peripartum depression in European countries. Methods: A systematic review according to the PRISMA statement was conducted. CPGs focussing on peripartum depression or with at least one specific recommendation for peripartum depression from European countries were selected. Searching was conducted in electronic databases (MEDLINE and PsycINFO), and by contacting professional societies and international experts until November 24th, 2021. Characteristics of the included CPGs and their recommendations were extracted. A methodological quality assessment was conducted using the AGREE-II tool. Results: A total of 239 records were identified after duplicate removal. Of these, 54 were examined for full-text inspection. The final selection yielded 14 CPGs from 11 European countries in 10 languages. Of them, 11 provided recommendations on pharmacological treatments, 10 on psychological treatment (e.g., cognitive-behavioural therapy), 10 on screening, 8 on diagnosis, 6 on other treatments (e.g., physical exercise), 5 on prevention, and 5 other recommendations (e.g., provide information). Regarding the overall methodological quality, only five (35.7%) guidelines were rated as of adequate quality, reaching a score ≥ 70% in the overall assessment of the AGREE-II instrument. Of the six AGREE-II domains, applicability scored the lowest and clarity of presentation scored the highest. Conclusion: The absence of CPGs in most European countries, the discrepancy in recommendations and the low methodological quality of the guidelines may lead to disparities and inequalities in peripartum depression management in Europe. The COST Action Riseup-PPD highlights key considerations for future guideline developers.
UR - http://www.scopus.com/inward/record.url?scp=85136532171&partnerID=8YFLogxK
U2 - 10.1111/acps.13478
DO - 10.1111/acps.13478
M3 - Review article
C2 - 35838293
AN - SCOPUS:85136532171
SN - 0001-690X
VL - 146
SP - 325
EP - 339
JO - Acta Psychiatrica Scandinavica
JF - Acta Psychiatrica Scandinavica
IS - 4
ER -